Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

12/3/2024

Janusmed kön och genus

Janusmed kön och genus – Acetylsalicylsyra Actavis

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Acetylsalicylsyra - lågdos Testmiljö

Acetylsalicylsyra - lågdos

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. Capodanno D, Angiolillo DJ. Impact of race and gender on antithrombotic therapy. Thromb Haemost. 2010;104:471-84.

  2. TROMBYL (acetylsalicylic acid). Summary of Product Characteristics. Medical Products Agency Sweden; 2017.

  3. Patti G, De Caterina R, Abbate R, Andreotti F, Biasucci LM, Calabrò P et al. Platelet function and long-term antiplatelet therapy in women: is there a gender-specificity? A 'state-of-the-art' paper. Eur Heart J. 2014;35(33):2213-23b.

  4. Rosenkranz B, Frölich JC. Plasma concentrations and anti-platelet effects after low dose acetylsalicylic acid. Prostaglandins Leukot Med. 1985;19(3):289-300.

  5. Husted SE, Pedersen AK, Petersen T, Geday E. Systemic availability of acetylsalicylic acid in normal men and women and its effect on in vitro platelet aggregability. Eur J Clin Pharmacol. 1983;24:679-82.

  6. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. 2006;295:306-13.

  7. Yerman T, Gan WQ, Sin DD. The influence of gender on the effects of aspirin in preventing myocardial infarction. BMC Med. 2007;5:29.

  8. Adelman EE, Lisabeth L, Brown DL. Gender differences in the primary prevention of stroke with aspirin. Womens Health (Lond Engl). 2011;7:341-52; quiz 352-3.

  9. Meyer DM, Eastwood JA, Compton MP, Gylys K, Zivin JA, Ovbiagele B. Sex differences in antiplatelet response in ischemic stroke. Womens Health (Lond Engl). 2011;7:465-74.

  10. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293-304.

  11. Xie M, Shan Z, Zhang Y, Chen S, Yang W, Bao W et al. Aspirin for primary prevention of cardiovascular events: meta-analysis of randomized controlled trials and subgroup analysis by sex and diabetes status. PLoS One. 2014;9(10):e90286.

  12. Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849-60.

  13. Sacco S, Cerone D, Carolei A. Gender and stroke: acute phase treatment and prevention. Funct Neurol. 2009;24:45-52.

  14. Chiang N, Hurwitz S, Ridker PM, Serhan CN. Aspirin has a gender-dependent impact on antiinflammatory 15-epi-lipoxin A4 formation: a randomized human trial. Arterioscler Thromb Vasc Biol. 2006;26:e14-7.

  15. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001;88:230-5.

  16. Sadiq PA, Puri A, Dixit M, Ghatak A, Dwivedi SK, Narain VS et al. Profile and prevalence of aspirin resistance in Indian patients with coronary artery disease. Indian Heart J. 2005;57:658-61.

  17. Kojuri J, Mahmoody Y, Zangbar Sabegh B, Jannati M, Mahboodi A, Khalili A. Dose-related effect of aspirin on laboratory-defined platelet aggregation and clinical outcome after coronary stenting. Cardiovasc Ther. 2010;28:147-52.

  18. Cao Y, Nishihara R, Wu K, Wang M, Ogino S, Willett WC et al. Population-wide Impact of Long-term Use of Aspirin and the Risk for Cancer. JAMA Oncol. 2016;2(6):762-9.

  19. Ye X, Fu J, Yang Y, Chen S. Dose-risk and duration-risk relationships between aspirin and colorectal cancer: a meta-analysis of published cohort studies. PLoS One. 2013;8(2):e57578.

  20. Jiang HY, Huang TB, Xu L, Yu J, Wu Y, Geng J et al. Aspirin use and lung cancer risk: a possible relationship? Evidence from an updated meta-analysis. PLoS One. 2015;10(4):e0122962.

  21. Li S, Liu Y, Zeng Z, Peng Q, Li R, Xie L et al. Association between non-steroidal anti-inflammatory drug use and melanoma risk: a meta-analysis of 13 studies. Cancer Causes Control. 2013;24(8):1505-16.

  22. Liu Y, Lu Y, Wang J, Xie L, Li T, He Y et al. Association between nonsteroidal anti-inflammatory drug use and brain tumour risk: a meta-analysis. Br J Clin Pharmacol. 2014;78(1):58-68.

  23. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2017 [cited 2018-04-17.]

  1. Capodanno D, Angiolillo DJ. Impact of race and gender on antithrombotic therapy. Thromb Haemost. 2010;104:471-84.
  2. TROMBYL (acetylsalicylic acid). Summary of Product Characteristics. Medical Products Agency Sweden; 2017.
  3. Patti G, De Caterina R, Abbate R, Andreotti F, Biasucci LM, Calabrò P et al. Platelet function and long-term antiplatelet therapy in women: is there a gender-specificity? A 'state-of-the-art' paper. Eur Heart J. 2014;35(33):2213-23b.
  4. Rosenkranz B, Frölich JC. Plasma concentrations and anti-platelet effects after low dose acetylsalicylic acid. Prostaglandins Leukot Med. 1985;19(3):289-300.
  5. Husted SE, Pedersen AK, Petersen T, Geday E. Systemic availability of acetylsalicylic acid in normal men and women and its effect on in vitro platelet aggregability. Eur J Clin Pharmacol. 1983;24:679-82.
  6. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. 2006;295:306-13.
  7. Yerman T, Gan WQ, Sin DD. The influence of gender on the effects of aspirin in preventing myocardial infarction. BMC Med. 2007;5:29.
  8. Adelman EE, Lisabeth L, Brown DL. Gender differences in the primary prevention of stroke with aspirin. Womens Health (Lond Engl). 2011;7:341-52; quiz 352-3.
  9. Meyer DM, Eastwood JA, Compton MP, Gylys K, Zivin JA, Ovbiagele B. Sex differences in antiplatelet response in ischemic stroke. Womens Health (Lond Engl). 2011;7:465-74.
  10. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293-304.
  11. Xie M, Shan Z, Zhang Y, Chen S, Yang W, Bao W et al. Aspirin for primary prevention of cardiovascular events: meta-analysis of randomized controlled trials and subgroup analysis by sex and diabetes status. PLoS One. 2014;9(10):e90286.
  12. Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849-60.
  13. Sacco S, Cerone D, Carolei A. Gender and stroke: acute phase treatment and prevention. Funct Neurol. 2009;24:45-52.
  14. Chiang N, Hurwitz S, Ridker PM, Serhan CN. Aspirin has a gender-dependent impact on antiinflammatory 15-epi-lipoxin A4 formation: a randomized human trial. Arterioscler Thromb Vasc Biol. 2006;26:e14-7.
  15. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001;88:230-5.
  16. Sadiq PA, Puri A, Dixit M, Ghatak A, Dwivedi SK, Narain VS et al. Profile and prevalence of aspirin resistance in Indian patients with coronary artery disease. Indian Heart J. 2005;57:658-61.
  17. Kojuri J, Mahmoody Y, Zangbar Sabegh B, Jannati M, Mahboodi A, Khalili A. Dose-related effect of aspirin on laboratory-defined platelet aggregation and clinical outcome after coronary stenting. Cardiovasc Ther. 2010;28:147-52.
  18. Cao Y, Nishihara R, Wu K, Wang M, Ogino S, Willett WC et al. Population-wide Impact of Long-term Use of Aspirin and the Risk for Cancer. JAMA Oncol. 2016;2(6):762-9.
  19. Ye X, Fu J, Yang Y, Chen S. Dose-risk and duration-risk relationships between aspirin and colorectal cancer: a meta-analysis of published cohort studies. PLoS One. 2013;8(2):e57578.
  20. Jiang HY, Huang TB, Xu L, Yu J, Wu Y, Geng J et al. Aspirin use and lung cancer risk: a possible relationship? Evidence from an updated meta-analysis. PLoS One. 2015;10(4):e0122962.
  21. Li S, Liu Y, Zeng Z, Peng Q, Li R, Xie L et al. Association between non-steroidal anti-inflammatory drug use and melanoma risk: a meta-analysis of 13 studies. Cancer Causes Control. 2013;24(8):1505-16.
  22. Liu Y, Lu Y, Wang J, Xie L, Li T, He Y et al. Association between nonsteroidal anti-inflammatory drug use and brain tumour risk: a meta-analysis. Br J Clin Pharmacol. 2014;78(1):58-68.
  23. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2017 [cited 2018-04-17.]